semaglutide for mash in with F2-F3 fibrosis: a holistic perspective on the ESSENCE phase 3 trial FDA Grants Accelerated Approval of
Description
The cardiovascular benefits, demonstrated in the SELECT trial showing reduced heart attack and stroke risk with semaglutide, actually argue in favor of continued use for people with cardiovascular risk factors
Patients often report reductions in hunger, heightened fullness after meals, diminished cravings, increased energy, and better levels in blood pressure, cholesterol, and blood sugar
We are currently in an internal evaluation phase, reviewing the published research and running a structured internal protocol with our clinical team
Comprehensive care: The best clinics offer more than prescriptions they include lab testing, nutritional counseling, and ongoing follow-up
Not as a luxury
